Research Area
Product Type
United States ( Change Country )
ZSTK474 Chemical Structure
Recommended Products
BEZ235 (NVP-BEZ235)
BEZ235 (NVP-BEZ235)is a dual ATP-competitive phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM，respectively.
Perifosine
Perifosine is an Akt inhibitor. the antiproliferative properties of perifosine with an IC50 of 0.6–8.9 µM.
PI-103
PI-103 is a potent, cell-permeable, ATP-competitive PI3K family member inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively.
GDC-0941
Inhibitor of Class I PI3 Kinase,p110a IC50=0.003uM,U87MG IC50=0.95μM.
LY294002
LY294002 is a PI3k inhibitor (cell IC50 about 10 μM) and a casein kinase II inhibitor.
XL147
XL147 is a selective inhibitor of Class I PI3K isoforms.
TGX-221
TGX-221 is a low-nanomolar range PI3Kβ inhibitor (IC50=10nM), shows about 1000-fold higher selectivity over PI3Kα, and is cell permeable. Order TGX-221 from supplier Selleck for research use only.
PIK-90
PIK-90 is a PI3K inhibitor,IC50=11, 350, 18, and 58 for p110 α, β, γ and δ isoforms.
PIK-75
PIK-75 Hydrochloride is a hydrochloride salt form of PIK-75, which is a preferential p110α/γ forms of PI3K inhibitor with IC50 of 6, 1300, 76, 510 nM for p110α, p110β, p110γ, p110δ, respectively.
YM201636
YM201636 is a novel PIKfyve-specific inhibitor with an IC50 of 54 nM for the net insulin response.
Biological Activity
ZSTK474 is an inhibitor of PI3K γ (IC50 at 6 nM). This agent inhibits PI3K α and PI3K β with IC50 of 17 and 53 nM, respectively. ZSTK474 was identified from a chemical library of about 1500 triazine derivatives, and selected for their ability to block tumor cell growth. In preclinical studies ZSTK474 was orally administered to mice and displayed a strong anti-tumoral activity in xenograft models. Toxicity was reported to be moderate. [1]
References on ZSTK474
- [1] Biochimica et Biophysica Acta 2008;1784: 159–185
- [2] Journal of the National Cancer Institute April 19, 2006;98:545-556
Chemical Information
| Molecular Weight (WM): | 417.41 |
|---|---|
| Formula: | C19H21F2N7O2 |
| CAS No.: | 475110-96-4 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥21mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
Quality Control & MSDS
Research Area
Notes:
Related Inhibitors
Related Antibodies
Recommended Screening Libraries
Chemical Library
A collection of 864 bioactive compounds
Inhibitor Library
A collection of 481 inhibitors
Kinase Inhibitor Library
A collection of 194 kinase inhibitors
Tyrosine Kinase Inhibitor Library
A collection of 85 tyrosine kinase inhibitors.
FDA Approved Drug Library
A collection of 426 FDA approved drugs
Natural Product Library
A collection of 139 natural products
Chemotherapeutic Agent Library
A collection of 40 chemotherapeutic agents
Epigenetics Compound library
A unique collection of 17 small molecule modulators
Stem Cell Compound library
A unique collection of 47 small molecule inhibitors
GPCR Compound library
A unique collection of 63 GPCR small molecules
We have 2 customer reviews of ZSTK474.
- (0)
- (1)
- (1)
- (0)
- (0)
- (0)
- (0)
- (0)
- (0)
Average Customer Review
(2 customer reviews)
-
Click to enlarge
We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.
We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.
Data independently produced by Saraswati Sukumar of Johns Hopkins University School of Medicine---ZSTK474 purchased from Selleck ZSTK474 purchased from Selleck
-
Click to enlarge
Western blot analysis of Akt and p-Akt. 0-20μM ZSTK474 was added.
Western blot analysis of Akt and p-Akt. 0-20μM ZSTK474 was added.
Data independently produced by Dr. Zhang of Tianjin Medical University ZSTK474 purchased from Selleck
Check our customer reviews
We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.
|
Data independently produced by Saraswati Sukumar of Johns Hopkins University School of Medicine---ZSTK474 purchased from Selleck
Western blot analysis of Akt and p-Akt. 0-20μM ZSTK474 was added. |
Data independently produced by Dr. Zhang of Tianjin Medical University
We give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) > See Details
Recently Viewed Items
Keywords:buy ZSTK474 | ZSTK474 supplier | purchase ZSTK474 | ZSTK474 cost | ZSTK474 manufacturer | order ZSTK474 | ZSTK474 distributor